Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review

2018 ◽  
Vol 12 (12) ◽  
pp. 1251-1263 ◽  
Author(s):  
Jaume Puig-Junoy ◽  
Natàlia Pascual-Argente ◽  
Lluc Puig-Codina ◽  
Laura Planellas ◽  
Míriam Solozabal
2020 ◽  
Vol 23 (9) ◽  
pp. 1180-1190 ◽  
Author(s):  
Ong The Due ◽  
Ammarin Thakkinstian ◽  
Montarat Thavorncharoensap ◽  
Abhasnee Sobhonslidsuk ◽  
Olivia Wu ◽  
...  

2020 ◽  
Vol 23 ◽  
pp. S174
Author(s):  
V.L. Ferreira ◽  
B. Riveros ◽  
L. Leonart ◽  
M.L.A. Pedroso ◽  
M.E. Nita ◽  
...  

2021 ◽  
pp. 1357633X2110324
Author(s):  
Elise Tan ◽  
Lan Gao ◽  
Huong NQ Tran ◽  
Dominique Cadilhac ◽  
Chris Bladin ◽  
...  

Introduction Telemedicine can alleviate the problems faced in rural settings in providing access to specialist stroke care. The evidence of the cost-effectiveness of this model of care outside high-income countries is limited. This study aimed to conduct: (a) a systematic review of economic evaluations of telestroke and (b) a cost–utility analysis of telestroke, using China as a case study. Methods We systematically searched Embase, Medline Complete and Cochrane databases. Inclusion criteria: full economic evaluations of telemedicine/telestroke networks examining the use of thrombolysis in patients with acute ischaemic stroke, published in English. A cost–utility analysis was undertaken using a Markov model incorporating a decision tree to simulate the delivery of telestroke for acute ischaemic stroke in rural China, compared to no telestroke from a societal and healthcare perspective. One-way deterministic sensitivity analyses and probabilistic sensitivity analyses were performed to test the robustness of results. Results Of 559 publications found, eight met the eligibility criteria and were included in the systematic review (two cost-effectiveness analyses and six cost–utility analyses, all performed in high-income countries). Telestroke was a cost-saving/cost-effective intervention in five out of the eight studies. In our modelled analysis for rural China, telestroke was the dominant strategy, with estimated cost savings of Chinese yuan 4,328 (US$627) and additional 0.0925 quality-adjusted life years per patient. Sensitivity analyses confirmed the base case results. Discussion Consistent with published economic evaluations of telestroke in other jurisdictions, telestroke represents a cost-effective solution to enhance stroke care in rural China.


Injury ◽  
2018 ◽  
Vol 49 (3) ◽  
pp. 575-584 ◽  
Author(s):  
S. Coyle ◽  
S. Kinsella ◽  
B. Lenehan ◽  
J.M. Queally

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e035224
Author(s):  
Haoya Yun ◽  
Guoqiang Zhao ◽  
Xiaojie Sun ◽  
Lizheng Shi

ObjectiveThis study aimed to estimate the cost–utility of sofosbuvir/velpatasvir (SOF/VEL) compared with other direct-acting antivirals (DAAs) in Chinese patients with hepatitis C virus (HCV).DesignA Markov model was developed to estimate the disease progression of patients with HCV over a lifetime horizon from the healthcare system perspective. Efficacy, clinical inputs and utilities were derived from the published literature. Drug costs were from the market price survey, and health costs for Markov health states were sourced from a Chinese study. Costs and utilities were discounted at an annual rate of 5%. One-way and probabilistic sensitivity analyses were conducted to test the impact of input parameters on the results.InterventionsSOF/VEL was compared with sofosbuvir+ribavirin (SR), sofosbuvir+dasabuvir (SD), daclatasvir+asunaprevir (DCV/ASV), ombitasvir/paritaprevir/ritonavir+dasabuvir (3D) and elbasvir/grazoprevir (EBR/GZR).Primary and secondary outcomesCosts, quality-adjusted life years (QALYs) and incremental cost–utility ratios (ICURs).ResultsSOF/VEL was economically dominant over SR and SD. However, 3D was economically dominant compared with SOF/VEL. Compared with DCV/ASV, SOF/VEL was cost-effective with the ICUR of US$1522 per QALY. Compared with EBR/GZR, it was not cost-effective with the ICUR of US$369 627 per QALY. One-way sensitivity analysis demonstrated that reducing the cost of SOF/VEL to the lower value of CI resulted in dominance over EBR/GZR and 3D. Probabilistic sensitivity analysis demonstrated that 3D was cost-effective in 100% of iterations in patients with genotype (GT) 1b and SOF/VEL was not cost-effective.ConclusionsCompared with other oral DAA agents, SOF/VEL treatment was not the most cost-effectiveness option for patients with chronic HCV GT1b in China. Lower the price of SOF/VEL will make it cost-effective while simplifying treatment and achieving the goal of HCV elimination.


2016 ◽  
Vol 33 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Ataru Igarashi ◽  
Wentao Tang ◽  
Ines Guerra ◽  
Lucile Marié ◽  
Sandrine Cure ◽  
...  

PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0229143 ◽  
Author(s):  
Rodolfo Castro ◽  
Hugo Perazzo ◽  
Letícia Artilles Mello Mendonça de Araujo ◽  
Isabella Gonçalves Gutierres ◽  
Beatriz Grinsztejn ◽  
...  

2019 ◽  
Vol 39 (9) ◽  
pp. 1652-1660 ◽  
Author(s):  
Marcus M. Mücke ◽  
Eva Herrmann ◽  
Victoria T. Mücke ◽  
Christiana Graf ◽  
Stefan Zeuzem ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document